LOS ANGELES (AP) — Biotechnology company CytRx Corp. said Tuesday it expects to respond to an FDA request for more information on a potential Lou Gehrig's disease treatment during the fourth quarter. In January, the FDA suspended a midstage study of the experimental drug arimoclomol citing the need for additional analysis. CyRtx said it will send its revised trial design to the FDA during the fourth quarter. If it is accepted, the company will be able to restart midstage development on the drug, potentially during the same quarter. Lou Gehrig's disease, a progressive condition that affects nerve cells in the brain and spinal cord, currently has no cure or treatment that halts or reverses the condition.